Malignant fibrous histiocytoma of the sinonasal tract

Head Neck. 2009 Jan;31(1):85-93. doi: 10.1002/hed.20936.


Background: Sinonasal malignant fibrous histiocytoma (MFH) is rare.

Methods: Twenty-five patients were registered with a diagnosis of sinonasal MFH at our hospital in the past 30 years. Clinical data were retrospectively reviewed.

Results: Eight tumors were primary MFH and 17 tumors were post-irradiated MFH, located within the radiation field for previous nasopharyngeal carcinoma. Twenty-one tumors originated from the maxillary sinus, 3 from the nasopharynx, and 1 from the nasal cavity. Twenty-three patients underwent surgery but only 12 tumors were removed completely. The 5-year overall and disease-free survival rates were 25.1% and 21.5%, respectively. Multivariate analyses showed that previous radiation was the only adverse prognostic factor for disease-free survival (p = .045). The 5-year disease-free survival rates of primary MFH and post-irradiated MFH were 72.9% and 0%.

Conclusion: In this series, post-irradiated MFH was more common than primary MFH. The prognosis of post-irradiated MFH is poor, whereas primary MFH is fair.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Disease-Free Survival
  • Female
  • Head and Neck Neoplasms / etiology
  • Head and Neck Neoplasms / mortality*
  • Head and Neck Neoplasms / radiotherapy
  • Head and Neck Neoplasms / surgery
  • Histiocytoma, Malignant Fibrous / etiology
  • Histiocytoma, Malignant Fibrous / mortality*
  • Histiocytoma, Malignant Fibrous / radiotherapy
  • Histiocytoma, Malignant Fibrous / surgery
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / radiotherapy*
  • Neoplasms, Radiation-Induced / epidemiology
  • Neoplasms, Radiation-Induced / mortality*
  • Prognosis
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • Young Adult